Intellia Therapeutics rises on narrower Q1 loss

Shares of gene-editing firm Intellia Therapeutics NTLA.O rise 3.4% to $7.54

NTLA reports Q1 net loss of $1.10 per share, narrower than the net loss of $1.12 a year ago

Posts Q1 collaboration revenue of $16.63 million, compared with $28.9 million a year ago

Co says it has cash and cash equivalents of $707.1 million as of March 31, with runway expected into H1 2027

Including session's moves, stock down 35.4% YTD